Table 2.
Patient characteristics
| N | % | |
|---|---|---|
| Gender | ||
| Female | 9 | 42.9 |
| Male | 12 | 57.1 |
| Age at diagnosis of primary UM, years | ||
| Median (IQR) | 61 (49–66) | |
| Age at diagnosis of UM metastasis, years | ||
| Median (IQR) | 65 (57–70) | |
| Metastasis site | ||
| Liver | 17 | 81.0 |
| Extra-hepatic | 4 | 19.0 |
| Liver involvement (n = 17), % | ||
| < 20 | 8 | 47.1 |
| 20–50 | 8 | 47.1 |
| > 50 | 1 | 5.8 |
| LDH | ||
| Normal | 15 | 71.4 |
| > 1ULN | 6 | 28.6 |
| Treatment | ||
| Checkpoint inhibitors immunotherapy | 13 | 61.9 |
| Targeted/Systemic therapies | 8 | 38.1 |
| Response | ||
| PD | 7 | 33.3 |
| SD | 7 | 33.3 |
| PR | 6 | 28.6 |
| CR | 1 | 4.8 |
| Status | ||
| Alive with disease | 11 | 52.4 |
| Dead | 10 | 47.6 |
Abbreviations: IQR interquartile range, N normal, ULN upper limit of normal, PD progressive disease, SD stable disease, PR partial response, CD complete response. Response evaluation for each patient was in accordance with RECIST 1.1 [30]